Spero Therapeutics (SPRO) Current Deferred Revenue (2016 - 2025)
Spero Therapeutics' (SPRO) quarterly Current Deferred Revenue came in at $258000.0 in Q4 2025, down 98.81% YoY from $21.8 million in Q4 2024, and down 98.81% on a QoQ basis from $21.8 million in Q4 2024.
Spero Therapeutics (SPRO) Current Deferred Revenue (2016 - 2025) Analysis & Trends
Spero Therapeutics (SPRO) has 8 years of Current Deferred Revenue data on file, last reported at $258000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 98.81% year-over-year to $258000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $258000.0 (down 98.81% YoY) and the FY2025 annual result came in at $258000.0, down 98.81% from the prior year.
- Current Deferred Revenue retreated to $258000.0 in Q4 2025, from $21.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $27.1 million in Q2 2024 to a low of $258000.0 in Q4 2025.
- A 5-year average of $8.0 million and a median of $6.0 million in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 920.45% — and 2025, when it plunged 98.81%.
- Tracing SPRO's Current Deferred Revenue over 5 years: stood at $1.9 million in 2021, then surged by 123.42% to $4.1 million in 2022, then slumped by 48.61% to $2.1 million in 2023, then surged by 920.45% to $21.8 million in 2024, then sank by 98.81% to $258000.0 in 2025.
- The last three Current Deferred Revenue figures came in at $258000.0 (Q4 2025), $21.8 million (Q4 2024), and $788000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Spero Therapeutics | 71.30 Mn | 20.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 258,000.00 |
| Dec 31, 2024 | 21.76 Mn |
| Sep 30, 2024 | 788,000.00 |
| Jun 30, 2024 | 27.14 Mn |
| Mar 31, 2024 | 2.87 Mn |
| Dec 31, 2023 | 2.13 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 8.71 Mn |
| Mar 31, 2023 | 11.85 Mn |
| Dec 31, 2022 | 4.15 Mn |
| Sep 30, 2022 | 3.73 Mn |
| Jun 30, 2022 | 7.89 Mn |
| Mar 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 1.86 Mn |
| Sep 30, 2021 | 9.20 Mn |
| Jun 30, 2021 | 9.93 Mn |
| Dec 31, 2018 | 229,000.00 |
| Sep 30, 2018 | 127,000.00 |
| Jun 30, 2018 | 126,000.00 |
| Mar 31, 2018 | 145,000.00 |